The FDA launched a pilot program pairing sponsors with prequalified research institutions to expedite Phase I trial IND preparation and review. The program supports rolling acceptance of IND components during the pre-IND phase, aiming to reduce delays between a sponsor’s IND work and first-in-human study initiation, while coordinating parallel steps like IRB review and site activation.